Partner Headlines - BIIB

  1. Biogen Misses On Tecfidera

    IBD
  2. With Market Back In Uptrend, IBD 50 Growth Names Thrive

    IBD
  3. Stocks Finish Solid Week; Akorn Restates 2014 Revenue

    IBD
  4. Biogen Shares Not Too Healthy After Q1 Miss

    Benzinga
  5. Chips Fall, But Nasdaq Holds Up; Avago Slices 50-Day Line

    IBD
  6. Stocks Firm Up As Amazon, Starbucks Gap To New Highs

    IBD
  7. Nasdaq Takes Lead In Mixed Open; Microsoft Surges, Biogen Dives

    IBD
  8. Biogen Q1 Misses Estimates As Tecfidera Stalls

    IBD
  9. Biogen Misses Q1 Estimates, Shares Slide

    Benzinga
  10. Must Watch Stocks for April 24, 2015

    Benzinga
  11. Earnings Scheduled For April 24, 2015

    Benzinga
  12. Biogen Earnings Preview: What To Look For

    IBD
  13. Making Money With Charles Payne: 04/23/15

    FoxBusiness
  14. Nasdaq Hits Record Close; Google, Amazon Rise After Hours

    IBD
  15. Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, ...

    GuruFocus
  16. Kyle Bass Challenges Biogen Fumaderm Patent

    Benzinga
  17. US Stock Futures Rise Ahead Of Earnings

    Benzinga
  18. PLEGRIDY 3-Year Data Presented at AAN Annual Meeting Support ...

    Benzinga
  19. CAR-T Therapy Stocks Hit Hard Following AACR Data

    Benzinga
  20. 5 Biotech Earnings Under The Microscope This Week

    Benzinga
  21. Meet 4 IBD 50 Companies Reporting Earnings This Week

    IBD
  22. How To Invest In ETFs: Tips To Trade Top Market Trends

    IBD
  23. 5 Top IBD 50 Stocks Stay On Course Despite Sell-Off

    IBD
  24. It's A Big Weekend For Biotech

    Benzinga
  25. Mr. Valuation disagrees with Henry Blodget: 'It's a Market of ...

    GuruFocus
  26. Receptos MS Drug Succeeds Against Ulcerative Colitis

    IBD
  27. New drug trial results positive

    IBD
  28. Pfizer, Biogen, AbbVie Get Good Drug-Trial News

    IBD
  29. Stock Futures Grapple Higher; Biogen, Akorn Lead IBD 50 List

    IBD
  30. GoPro, Avon and Intel Highlight Tuesday's After-Hours Movers

    Benzinga
  31. BIOGEN IDEC

    IBD
  32. Biogen Reports New Anti-LINGO-1 Phase 2 Acute Optic Neuritis ...

    Benzinga
  33. Top Funds Buying Rackspace, Allergan ogen Idec, Apple

    IBD
  34. Big Cap 20 Reflecting Market Leadership

    IBD
  35. How To Invest: Avoid Bases Of Low-Priced Stocks

    IBD
  36. Medivation Tops Q4 Views On Strong Xtandi Results

    IBD
  37. The Catalysts Biogen Idec Investors Should Watch

    Benzinga
  38. United Therapeutics Blood Pressure Drug Spurs Q4 Beat

    IBD
  39. Drugmaker Mylan Takes Part In Pharma Feeding Frenzy

    IBD
  40. Pharma M&A: Bristol-Myers, Valeant Make Deals

    IBD
  41. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  42. February Pick Of Biotech Stocks

    GuruFocus
  43. Stanley Druckenmiller's Recent Trades

    GuruFocus
  44. 8 Strong Recommendations for 2015

    GuruFocus
  45. Stocks End Mixed: Molina Healthcare Rises Again

    IBD
  46. Stocks Open Mixed, Techs Climb; Rite Aid, Akamai, AmTrust Jump

    IBD
  47. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  48. No Deceleration Here: 14 Stocks With Accelerating Profits

    IBD
  49. Nuveen's Bob Doll Runs Several Top Funds

    IBD
  50. Top Performing Funds Favor Leisure, Medical, REITs

    IBD
  51. iShares NASDAQ Biotech ETF Pulls Back Off All-Time Highs

    Benzinga
  52. Super Bowl Stocks: Seattle's Best Vs. Boston Strong

    IBD
  53. Many Leading Stocks Stumble But Biogen, Harman Soar

    IBD
  54. Stocks Slide Into Closing Bell; Day's Winners: Amazon, Biogen

    IBD
  55. Indexes Mired In Red; Amazon, Biogen, Visa Buck Trend

    IBD
  56. Stocks Extend Losses; Biogen Idec Gains

    IBD
  57. Stocks Open Down In Weak Trade; Biogen, Visa Soar On Q4 Results

    IBD
  58. Stocks Hitting 52-Week Highs

    Benzinga
  59. Morning Market Gainers

    Benzinga
  60. Friday Morning Movers: Amazon Pops, Deckers Outdoor Plummets ...

    Benzinga
  61. Biotechs' Earnings Buoy Street Despite FX Headwinds

    IBD
  62. Biogen, Alexion Soar On EPS

    IBD
  63. Making Money With Charles Payne: 01/29/15

    FoxBusiness
  64. Biogen Idec Q4 Net Nearly Doubles; Beats Views

    Benzinga
  65. Alexion Beats Q4 Estimates, Appoints New CEO

    IBD
  66. Credit Suisse Previews Biogen, Says 'Consensus Tecfidera Downgrades ...

    Benzinga
  67. Earnings Scheduled For January 29, 2015

    Benzinga
  68. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  69. Stocks Fade Badly; EA Hangs Tough

    IBD
  70. Earnings Scheduled For January 28, 2015

    Benzinga
  71. Must Watch Stocks for January 28, 2015

    Benzinga
  72. Big Cap Stocks Mylan, American Tower Near Buy Points

    IBD
  73. 5 Big Biotech Earnings Releases To Watch This Week

    Benzinga
  74. Apple, Facebook Lead This Week's IBD 50 Earnings

    IBD
  75. Apple, Facebook Lead Top IBD 50 Earnings This Week

    IBD
  76. IBD 50 Turns In Solid Week As Market Uptrend Resumes

    IBD
  77. The 5 Biggest Biotech Stocks

    Benzinga
  78. Jefferies 'Encouraged' By Biogen Idec's New Data

    Benzinga
  79. Nomura's Takeways From Biogen Idec's Analyst Meeting

    Benzinga
  80. Biogen Idec To Acquire Convergence Pharmaceuticals In Deal Worth ...

    Benzinga
  81. Meet 5 Top Medical Stocks Making Waves This Week

    IBD
  82. Stocks Turn Negative; Goodyear Triggers Sell Signal

    IBD
  83. A Look At 3 Biotech Stocks With Upside Potential

    Benzinga
  84. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  85. Stocks Reverse Lower On Good News/Bad News Job Data

    IBD
  86. Biogen drug results mixed

    IBD
  87. Nasdaq, S&P 500 Gap Up At Open, Hold Strong Gains

    IBD
  88. Biogen Nerve-Repair Drug Yields Mixed Results

    IBD
  89. Stock Market Surges; Nasdaq, S&P 500 Retake 50-Day Lines

    IBD
  90. Stocks Poised For Early Pop; Global Payments Gains

    IBD
  91. Stock Indexes Gun For Best Pop In 3 Weeks; Monster Breaks Out

    IBD
  92. Late-Session Rally Fades; Stocks End Firmly Lower

    IBD
  93. Oil's Drop Spooks Market Again, But REITs Outperform

    IBD
  94. Stocks Take It On The Chin Again; 10-Year Yield Plummets

    IBD
  95. J.P. Morgan Chimes In With Ratings On BioTech Stocks

    GuruFocus
  96. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  97. Benzinga's Top Initiations

    Benzinga
  98. Barclays Initiates Biogen Idec At Overweight

    Benzinga
  99. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  100. Isis Pharma To Develop GI Drugs With J&J

    IBD
Trading Center